Sugi Predict

Sugi Predict / Compounds / SCHEMBL10067290

SCHEMBL10067290

SCHEMBL10067290

CC(C)(C)c1[nH]c2ccccc2c1-c1nc2c3cccnc3c3ncccc3c2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK4 P11802 1/20 0.41
▸ CCND1 P24385 1/20 0.41
▸ PARP1 P09874 3/20 0.40
▸ GABRA1 P14867 2/20 0.38
▸ GABRG2 P18507 2/20 0.38
▸ GABRB3 P28472 2/20 0.38
▸ GABRA5 P31644 2/20 0.38
▸ GABRA3 P34903 2/20 0.38
▸ GABRA2 P47869 2/20 0.38
▸ KDM4E B2RXH2 4/20 0.37
▸ MAPT P10636 4/20 0.37
▸ HPGD P15428 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ FLT1 P17948 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067287 0.90 KIF11 (0.45) CDK4CCND1PARP1GABRA1GABRG2
SCHEMBL16624849 0.90 PTGES (0.41) CDK4CCND1GABRA1GABRG2GABRB3
SCHEMBL16629095 0.89 GSK3A (0.35) CDK4CCND1PARP1GABRA1GABRG2
SCHEMBL10067297 0.89 PTGES (0.37) CDK4CCND1KDM4EMAPTHPGD
SCHEMBL10067328 0.89 PTGES (0.43) CDK4CCND1GABRA1GABRG2GABRB3
SCHEMBL10067315 0.88 PTGES (0.40) CDK4CCND1GABRA1GABRG2GABRB3
SCHEMBL10067285 0.87 PTGES (0.41) CDK4CCND1KDM4EMAPTALDH1A1
SCHEMBL10067300 0.86 CDK4 (0.33) CDK4CCND1PARP1GABRA1GABRG2
SCHEMBL10082768 0.86 L3MBTL1 (0.41) MEN1KMT2APTGESJAK2TDO2
SCHEMBL10067308 0.84 HDAC6 (0.38) PARP1GABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
WO-2010102393-A1 2-INDOLYL IMIDAZO [4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT ANGIOGENESIS LORUS THERAPEUTICS INC. (CA) 2010-09-16 — — WO disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 CDK4 1126/4885CCND1 200/4885PARP1 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.